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Abstract
Background: The immune modulatory effect of granulocyte colony-stimulating factor (G-CSF) on T cells resulted in
an unexpected low incidence of graft-versus-host disease (GVHD) in allogeneic peripheral blood stem cell
transplantation (allo-PBSCT). Recent data indicated that gamma delta
+ T cells might participate in mediating graft-
versus-host disease (GVHD) and graft-versus-leukemia (GVL) effect after allogeneic hematopoietic stem cell
transplantation. However, whether G-CSF could influence the T cell receptors (TCR) of gamma delta
+ T cells (TRGV
and TRDV repertoire) remains unclear. To further characterize this feature, we compared the distribution and
clonality of TRGV and TRDV repertoire of T cells before and after G-CSF mobilization and investigated the
association between the changes of TCR repertoire and GVHD in patients undergoing G-CSF mobilized allo-PBSCT.
Methods: The complementarity-determining region 3 (CDR3) sizes of three TRGV and eight TRDV subfamily genes
were analyzed in peripheral blood mononuclear cells (PBMCs) from 20 donors before and after G-CSF mobilization,
using RT-PCR and genescan technique. To determine the expression levels of TRGV subfamily genes, we performed
quantitative analysis of TRGVI~III subfamilies by real-time PCR.
Results: The expression levels of three TRGV subfamilies were significantly decreased after G-CSF mobilization (P =
0.015, 0.009 and 0.006, respectively). The pattern of TRGV subfamily expression levels was TRGVII >TRGV I> TRGV III
before mobilization, and changed to TRGV I> TRGV II >TRGV III after G-CSF mobilization. The expression frequencies
of TRGV and TRDV subfamilies changed at different levels after G-CSF mobilization. Most TRGV and TRDV subfamilies
revealed polyclonality from pre-G-CSF-mobilized and G-CSF-mobilized samples. Oligoclonality was detected in TRGV
and TRDV subfamilies in 3 donors before mobilization and in another 4 donors after G-CSF mobilization, distributed
in TRGVII, TRDV1, TRDV3 and TRDV6, respectively. Signiﬁcant positive association was observed between the
invariable clonality of TRDV1 gene repertoire after G-CSF mobilization and low incidence of GVHD in recipients (P =
0.015, OR = 0.047).
Conclusions: G-CSF mobilization not only influences the distribution and expression levels of TRGV and TRDV
repertoire, but also changes the clonality of gamma delta
+ T cells. This alteration of TRGV and TRDV repertoire
might play a role in mediating GVHD in G-CSF mobilized allo-PBSCT.
Background
Recently, the peripheral blood stem cells (PBSCs)
obtained from granulocyte colony-stimulating factor (G-
CSF) mobilized donors has been used more frequently
than bone marrow stem cells as the source of stem cells
in allogeneic hematopoietic stem cell transplantation
(allo-HSCT). The clinical advantages of G-CSF-mobi-
lized peripheral blood stem cell transplantation (G-
PBSCT) accelerate engraftment and shorten the neutro-
penic period compared with bone marrow transplanta-
tion (BMT)[1,2]. In G-CSF mobilized allogeneic
peripheral blood stem cell transplantation (allo-PBSCT),
despite the presence of a more than 10-fold higher
number of mature T cells in the graft, the incidence or
severity of graft-versus-host disease (GVHD), especially
acute GVHD, is not elevated compared with BMT [2,3].
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any medium, provided the original work is properly cited.Some studies suggested that the protective effects of G-
CSF against GVHD might result from the immune mod-
ulatory effect of G-CSF on T cells, including that G-CSF
directly modulated via its receptor on T cells or indir-
ectly modulated T cell immune responses via effector
cells and cytokines [4-8].
T cells recognize specific ligands by specific T cell
receptors (TCR), which are heterodimers comprising
either a/b or g/δ chains. Genes encoding the variable
domains of the TCR g and δ heterodimer chains are
TRG (g chain) and TRD (δ chain), which are assembled
by somatic recombination from variable (V), diversity
(D, only for TRD), and joining (J) segments [9-11]. The
TRG gene contains at least 14 functional variable
(TRGV) segments belonging to four subgroups (TRGVI
to IV), and the TRD contains at least 8 functional
TRDV segments, which are subdivided into 8 TRDV
subfamilies (TRDV1t o TRDV8)[12-14]. The functional
capacities of gδ
+ T cells include cytokine production and
potent cytotoxic effector activity [15-17]. Recently, it
was reported that gδ
+ T cells might participate in regu-
lation of autoimmune diseases and GVHD [16,18-21].
However, it is still unclear whether G-CSF mobilization
could influence gδ
+ T cells and thereby mediate GVHD.
In the present study, to further investigate the immune
modulatory effect of G-CSF on T cells, we characterized
the distribution and clonality of TRGV and TRDV subfa-
milies of donor T cells before and after G-CSF
mobilization.
Methods
Samples
Peripheral blood was obtained from 20 healthy stem cell
donors (9 female, 11 male; median age 30 years, range
14-56 years) before mobilization and on fifth day of
mobilization with G-CSF (Filgrastim, subcutaneous
injection of 5 μg/kg/d; Kirin Brewery Co, Tokyo, Japan).
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from peripheral blood samples by Ficoll-Hypaque
gradient centrifugation. The twenty healthy stem cell
donors were willing to accept the trial after being
informed, and all samples were obtained with consent
from them. All the procedures were conducted accord-
ing to the guidelines of the local ethical review boards
before study initiation.
RNA isolation and cDNA synthesis
RNA was extracted from the PBMCs of donors before
and after G-CSF mobilization according to the manufac-
turer’s protocol (Trizol, Invitrogen, USA). The quality of
RNA was analyzed in 0.8% agarose gel stained with ethi-
dium bromide. Two μg RNA was reversely transcribed
into the first single-stranded cDNA with random hex-
amer primers, using reverse transcriptase of the
Superscript II Kit (Gibco, USA). The quality of cDNA
was confirmed by RT-PCR for b2 microglubin (b2M)
gene amplification.
RT-PCR for TRGV and TRDV subfamily amplification
As TRGVIV is a pseudogene [16], the analysis of TRGV
repertoire was acquired in three TRGV subfamilies in
the present study. Three sense TRGV primers and a sin-
gle TRGC reverse primer, or 8 TRDV sense primers and
as i n g l eTRDC primer were used in unlabeled PCR for
amplification of the TRGV and TRDV subfamilies
respectively. Subsequently, a runoff PCR was performed
with fluorescent primers labeled at 5’end with the FAM
fluorophore (Cg-FAM or Cδ-FAM). Aliquots of the
cDNA (1 μl) were amplified in 20 μl mixture with one
of the 3 Vg primers and a Cg primer or one of 8 Vδ pri-
mers and a Cδ primer. The final mixture contained 0.5
μM sense primer and antisense primer, 0.1 mM dNTP,
1.5 mM MgCl2,1×P C Rb u f f e ra n d1 . 2 5UT a qp o l y -
merase (Promega, USA). The amplification was per-
formed on a DNA thermal cycler (BioMetra, Germany)
with 3 min denaturation at 94°C and 40 PCR cycles.
Each cycle consisted of 94°C for 1 min, 60°C for 1 min
and 72°C for 1 min respectively, and a final 7 min elon-
gation at 72°C. All PCR products were stored at 4°C and
ready for genescan analysis [16,22].
Genescan analysis for TRGV and TRDV subfamily clonality
Aliquots of the unlabeled PCR products (2.5 μl) were
separately added to a final 10 μl reaction system con-
taining 0.1 μMC g-FAM or Cδ-FAM primer, 0.2 mM
dNTP, 3 mM MgCl2, PCR buffer and 0.25 U Taq poly-
merase (Promega, USA). After a 3 min denaturation at
94°C, 35 cycles of amplification were carried out (1 min
at 94°C, 1 min at 66°C and 1 min at 72°C and a final 6
min elongation at 72°C). The labeled runoff PCR pro-
ducts (2.5 μl) were heat denatured at 94°C for 4 min
with 9.5 μl formamide (Hi-Di Formamide, ABI, USA)
and 0.5 μl of Size Standards (GENESCAN™-500-LIZ™
Perkin Elmer, ABI). The samples were then loaded on
3100 POP-4™ gel (Performance Optimized Polymer-4,
ABI, USA) and resolved by electrophoresis in 3100
DNA sequencer (ABI, Perkin Elmer) for size and fluor-
escance intensity analysis using Genescan software
[16,22].
Real-time quantitative PCR (RQ-PCR) for TRGV gene
Real-time PCR with SYBR Green I technique was used
to examine TRGVI-III subfamily gene expression level
in cDNA of PBMCs from 20 peripheral blood samples,
the b2-microglobulin gene was used as an internal refer-
ence, the folds of change of TRGVI-III gene expression
l e v e lw e r eu s e db yt h e2
-ΔCt method. Briefly, PCR in
20 μl total volume was performed with approximately
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I-III sense primer and the antisense primer Cg for
TRGVI-III amplification, b2M-for and b2M-back primers
for b2-microglobulin gene amplification) and 2.5 ×
RealMasterMix 9 μl (Tiangen, China). After the initial
denaturation at 95°C for 2 min, 45 cycles consisting of
95°C 15 s, 60°C 60 s and 82°C 1 s for plate reading were
performed using MJ Research DNA Engine Opticon 2
PCR cycler (BIO-RAD, USA). The relative mRNA
expression level of TRGVI-III gene in each sample was
calculated according to the comparative cycle time (Ct)
method. Briefly, the target PCR Ct value, that is, the
cycle number at which emitted fluorescence exceeds the
10 × SD of baseline emissions, is normalized by sub-
tracting the b2M Ct value from the target PCR Ct value,
which gives the ΔCt value. From this ΔCt value, the
relative expression level to b2M for each target PCR can
be calculated using the following equation: relative
mRNA expression = 2
-ΔCt × 100% (ΔCt = Ct(TRGV) -C t
(b2M)) [16,22].
Statistical analysis
Univariate analyses were performed using the Wilcoxon
matched pair test to compare medians of TRGV or
TRDV subfamilies between pre-G-CSF-mobilized and
G-CSF-mobilized groups. McNemar’s test was used for
comparison of the expression frequencies of TRGV or
TRDV subfamilies between two groups. Differences in
mRNA expression of TRGVI-III between two groups
were analyzed using the Wilcoxon matched pair test.
Kruskal-Wallis Test was used for comparison of differ-
ent gene expression levels from three TRGV subfamilies
before or after G-CSF mobilization, and bonferroni cor-
rection was used for pairwise comparisons. Binary logis-
tic regression analysis was used to estimate the
association between GVHD in recipients and the altera-
tion of each TRGV and TRDV repertoire after G-CSF
mobilization. GVHD was considered as the dichotomous
dependent variable and the changes of all TRGV and
TRDV repertoires after G-CSF mobilization were con-
sidered as the covariates. P < 0.05 was considered as sta-
tistically significant (P < 0.0167 was considered as
statistically significant in bonferroni correction).
Results
The expression pattern and levels of TRGV repertoire
before and after G-CSF mobilization
The CDR3 sizes and expression levels of three TRGV
subfamily genes in T cells were respectively analyzed by
RT-PCR in 20 donors before and after G-CSF mobiliza-
tion. The results showed that the expression frequencies
of TRGVI, TRGVII and TRGVIII before mobilization
were 95% (19/20), 65% (13/20) and 95% (19/20), respec-
tively. After G-CSF mobilization, similar expression
frequencies were found in TRGVI (95%, 19/20), TRGVII
(45%, 9/20) and TRGVIII (100%, 20/20) (P > 0.05) (Fig-
ure 1). Although the expression frequency of TRGVII
decreased 20% after G-CSF mobilization, McNemar’s
test showed that there was no significant difference in
expression frequency of TRGVII between pre-G-CSF
and post-G-CSF group (P = 0.344). In addition, the
expression levels of TRGVI, TRGVII and TRGVIII genes
after G-CSF mobilization were significantly lower than
that before mobilization (P = 0.015, 0.009 and 0.006,
respectively), quantified by 2
-ΔCt method (Figure 2). The
pattern of TRGV expression levels before mobilization
revealed as TRGVII >TRGVI> TRGVIII, and there was a
significant difference among the expression levels of
three TRGV subgroups (c
2 = 8.528, P = 0.014, Kruskal-
Wallis test). However, after G-CSF mobilization, it
revealed the TRGV I> TRGV II >TRGV III pattern and
there was also a significant difference among three
TRGV subfamily groups (c2 = 6.933, P = 0.031, Kruskal-
Wallis test) (Figure 2). Bonferroni correction was
applied to further compare the difference in each group,
there were significant differences between TRGVIa n d
TRGVIII before and after G-CSF mobilization (P =
0.004, 0.007, respectively), but there were no signiﬁcant
difference between TRGVII and TRGVIII (P = 0.031,
0.163, respectively), TRGVIa n dTRGVII (P = 0.582,
0.301, respectively) before and after G-CSF mobilization.
The expression pattern of TRDV repertoire before and
after G-CSF mobilization
In TRDV subfamilies, the number of detectable subfami-
lies ranged from 0 to 6 (median 2.12) before mobilization,
which was higher than that after mobilization (ranged
from 0 to 4, median 1.94, P > 0.05). The frequently
expressed members were TRDV1 (65%, 13/20), TRDV2
and TRDV5 (40%, 8/20), TRDV6 (35%, 7/20) and TRDV3
(30%, 6/20) before G-CSF mobilization, while TRDV1
(65%, 13/20), TRDV3 (50%, 10/20), TRDV2 (35%, 7/20),
TRDV6 (25%, 5/20) and TRDV5(20%, 4/20) after G-CSF
mobilization. TRDV7a n dTRDV8 were detected only in
one case before mobilization, and were not identified in
all samples after G-CSF mobilization (Figure 1). It could
be seen from Figure 1 that the alteration in the expres-
sion frequencies between two groups was mainly embo-
died in TRDV3 (20%, 4/20) and TRDV5 (20%, 4/20),
TRDV6 ( 1 0 % ,2 / 2 0 ) .H o w e v e r ,t h e r ew a sn os i g n i f i c a n t
difference between pre-G-CSF and post-G-CSF expres-
sion frequencies of TRDV3, TRDV5a n dTRDV6( P =
0.344, P = 0.219, P = 0.688, respectively).
The clonality of TRGV and TRDV subfamily T cells before
and after G-CSF mobilization
To compare the differences in TRGV and TRDV gene
repertoire diversity before and after G-CSF mobilization,
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files were examined using genescan analysis. Most PCR
products of TRGV and TRDV subfamilies displayed a
Gaussian distribution of CDR3 lengths (multi-peaks)
before and after G-CSF mobilization, which corre-
sponded to polyclonal rearrangement pattern, whereas
three PCR products in TRDV6 subfamily from 20 sam-
ples displayed oligoclonality before mobilization (Figure
3A). Clonal expansion was identified in another four
cases after G-CSF mobilization, distributed in TRGVII,
TRDV6, TRDV1a n dTRDV3 (Figure 3B). The three oli-
goclonal expanded TRDV6 T cells which were identified
before mobilization underwent alterations after G-CSF
mobilization, in which two cases changed to negative
and another one changed to polyclonality. Meanwhile,
two cases with TRDV6 absence and one case with
TRGVII absence before mobilization all changed to oli-
goclonality after G-CSF mobilization. Moreover, one
case without TRDV3 expression changed to oligoclonal-
ity, and its polyclonal expansion in TRDV1c h a n g e dt o
oligoclonality after G-CSF mobilization (Figure 4). The
alteration of clonality of TRGV and TRDV subfamilies
between two groups was mainly reflected in TRGVII
(50%, 10/20), TRDV3 (50%, 10/20), TRDV1 (45%, 9/20),
TRDV6 (35%, 7/20),T R D V 5( 3 0 % ,6 / 2 0 ) ,a n dTRDV2
(25%, 5/20) (Figure 3A and 3B).
Outcome in recipients undergoing allo-PBSCT
From March 2010 to October 2010, 20 patients received
G-CSF-mobilized allo-PBSCT from HLA-identical sib-
ling donors. In total, 11 recipients experienced GVHD
after transplantation, including 8 recipients with acute
GVHD (grade I in 3 and gradeII in 5) and 7 recipients
with chronic GVHD (3 extensive and 4 local). There-
into, 4 cases with chronic GVHD experienced acute
GVHD. We analyzed the association between GVHD
and the alteration of clonality of each TRGV and TRDV
repertoire after G-CSF mobilization. Simple effect analy-
sis of binary logistic regression showed that the invari-
able clonality of TRDV1 gene repertoire after G-CSF
mobilization was associated with low incidence of
GVHD (r = 0.616, P = 0.004), and the alteration of
other TRDV or TRGV subfamilies had no significant
association with GVHD. Multivariate analysis also
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Figure 1 The expression frequencies of TRGV and TRDV subfamilies in PBMCs from 20 donors before and after G-CSF mobilization.
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Page 4 of 9showed that the invariable clonality of TRDV1g e n e
repertoire after G-CSF mobilization indicated low inci-
dence of GVHD (P = 0.015, odds ratio (OR) = 0.047,
95% confidence interval (CI): 0.004-0.552), and it was no
signiﬁcant association between GVHD and the alteration
of expression levels of three TRGV subgroups after G-
CSF mobilization (P = 0.806, P = 0.458, P = 0.719,
respectively). Meanwhile, it could be seen from Figure 3
that the incidence of GVHD was 8/11 (27.2%) in the
TRDV1 clonality invariable group, whereas the incidence
of GVHD reached 8/9 (88.9%) in the TRDV1c l o n a l i t y
variable group. In addition, the alteration of expression
pattern of TRGV repertoire also was not significantly
associated with GVHD (P = 0.120).
Discussion
T h ei m m u n em o d u l a t o r ye f f e c to fG - C S Fo nTc e l l s
resulted in an unexpected low incidence of GVHD in
G-CSF mobilized allo-PBSCT. However, the underlying
mechanism for the reduced reactivity or alloreactivity of
T cells after G-CSF mobilization was not fully under-
stood [23,24]. A growing body of experimental evidence
s u g g e s t st h a tG - C S Fm i g h ti n t e r a c tw i t ht h ei m m u n e
system by altering T cell reactivity [23,25]. Some studies
suggested that G-CSF could directly modulate T-cell
immune responses via its receptor, which could be
detected on T cells [24,26]. However, whether the unac-
tivated T cells could express G-CSF receptor (G-CSFR)
remains unclear. Franzke’s study showed that the
expression of G-CSFR was undetected in the unactivated
T cells, but both CD4
+ and CD8
+ T cell could express
the G-CSFR at the mRNA level after G-CSF stimulation
in vivo or vitro [24]. Morikawa et al. also observed that
the unactivated T cells from peripheral blood did not
bind to the biotinylated G-CSF, but the active T cells
after Con A stimulation could bind to the biotinylated
G-CSF [26]. These studies suggested that the unacti-
vated T cells could express G-CSFR by stimulation
[23,24,26]. However, whether G-CSF directly modulates
T-cell immune responses via G-CSFR on T cells or T
cell receptor needs further investigation.
T cells are comprised of two major subpopulations,
identiﬁed by their expression of either the ab or gδ
TCR heterodimer. ab
+ T cells are the predominant cir-
culating population and can be subdivided into cells
that express CD4
+ or CD8
+ antigens. gδ
+ Tc e l l s ,w h i c h
represent approximately 5-10% of peripheral T cells and
are predominantly CD3
+ CD4
- CD8
- T cells [16,27],
recognize specific antigen without MHC-restriction and
are considered as linkage between innate and adaptive
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Figure 2 The pattern of TRGV I-III expression levels in PBMCs from 20 donors before and after G-CSF mobilization.
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Page 5 of 9immune response [28,29]. As a group of innate immune
cells, gδ
+ T cells respond rapidly and expand efficiently
when stimulated by antigens or cytokines and may be a
good target for modulation of immune responses in
human diseases. Recently, the role of gδ
+ T cells in med-
iating GVHD raised certain attention [30-36], but
whether gδ
+ T cells promoted or inhibited the occur-
rence of GVHD was still controversial. Several studies
showed that gδ
+ T cells might contribute to GVHD
[32-34], while others demonstrated that gδ
+ Tc e l l s
could inhibit GVHD [35,36]. The generation and main-
tenance of a diverse T-cell repertoire is a critical ele-
ment in immune competence. Therefore, it might be
interesting to further clarify whether G-CSF could
influence the distribution and clonality of TRGV and
TRDV repertoire of gδ
+ T cells, thereby influencing the
alloreactivity of T cells and mediating GVHD in G-CSF
mobilized allo-PBSCT.
In the present study, we investigated the feature of
distribution and clonality of TRGV and TRDV reper-
toire from healthy donors before and after G-CSF
mobilization. The results showed that G-CSF mobiliza-
tion could influence the distribution and clonality of
TRGV and TRDV repertoire of gδ
+ T cells. The expres-
sion levels of three TRGV subfamilies were signifi-
cantly decreased after G-CSF mobilization. In addition,
the pattern of TRGV expression levels also changed
after G-CSF mobilization, suggesting that G-CSF might
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Figure 3 Distribution and clonality of TRGV and TRDV subfamilies in PBMCs from 20 donors (D1-D20). (A) before G-CSF mobilization; (B)
after G-CSF mobilization. GVHD*: the status of graft-versus-host disease of the corresponding recipients after allogeneic peripheral blood stem
cell transplantation; a: acute graft-versus-host disease; c: chronic graft-versus-host disease.
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Page 6 of 9influence the expression pattern of TRGV subfamilies.
The expression frequencies of TRGV and TRDV subfa-
milies changed at different levels after G-CSF mobiliza-
tion; however, there were no significant differences in
the expression frequencies of all TRGV and TRDV sub-
families between pre-G-CSF and post-G-CSF group.
Most TRGV and TRDV subfamilies revealed polyclon-
ality from pre-G-CSF-mobilized and G-CSF-mobilized
samples. Oligoclonality was detected in TRGV and
TRDV subfamilies in 3 donors before mobilization and
in another 4 donors after G-CSF mobilization, distribu-
ted in TRGVII, TRDV1, TRDV3a n dTRDV6, respec-
tively. Recent studies suggested that some clonal T
cells might be a reaction to host alloantigen and
related with GVHD activity [37]. Meanwhile, it is
recognized that the persistent oligoclonal T cell expan-
sion could be incurred due to many factors affecting
the overall regulation of clone size in response to
chronic antigens [16,38]. Our studies revealed that the
two oligoclonal expanded TRDV6 T cells appeared in
two patients with aGVHD, while the expansion of the
TRGVII T cells, as well as the expansion of the
TRDV1a n dTRDV3 T cells appeared in two patients
without GVHD. Consequently, whether the change of
clonality was due to the effect of G-CSF or it was
r e l a t e dw i t hG V H Dn e e d sf u r t h e rs t u d y .H o w e v e r ,i t
was a pity that the donors were not followed up, as it
t o o kal o n gt i m et og e tt h er e s u l t s .
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Page 7 of 9Recently, researchers revealed that gδ
+ T cells pro-
duced a series of cytokines in pathology and played an
indispensable role in pathogen elimination, immune reg-
ulation and autoimmunity [39,40]. gδ
+ T cells modulated
immune responses mainly by secreting cytokines and by
regulating the function of other immune cells, such as
ab
+ T cells, macrophages, NK cells and CD4
+CD25
+Foxp3
+ regulatory T cells (Treg)and so on [41-44].
Despite the variety of characteristics attributed to gδ
+ T
cells, their exact role in mediating GVHD remained
unclear. Drobyski et al. postulated that transplantation
with gδ
+ T cells protected mice from GVHD [36],
whereas Blazar et al. showed that the infusion of donor
gδ
+ T cells induced lethal GVHD in mice [34]. However,
Anderson et al did not find any correlation between
host gδ
+ T cells and GVHD in mice [45]. Similarly in
human studies, Pabst et.al showed that it was a signifi-
cant association between an increased donor gδ
+ T cells
dose and the cumulative incidence estimates of aGVHD
[46], whereas Godder et al. observed that patients with
increased gδ
+ T cells recovery did not have an increased
incidence of GVHD compared to those with normal or
decreased numbers [20].
Different from most studies which analyzed from
angle of quantity of gδ
+ T cells, we studied from the
perspective of different repertoire of gδ
+ T cells (TRGV
and TRDV repertoire), which was thought to have dif-
ferent functions for immune response. Positive associa-
tion was observed between the invariable clonality of
TRDV1 gene repertoire after G-CSF mobilization and
low incidence of GVHD, and the invariable clonality of
TRDV1 gene repertoire after G-CSF mobilization indi-
cated low incidence of GVHD (OR =0 . 0 4 7 ) .D u et ot h e
small sample size, the association between GVHD and
other TRDV and TRGV subfamilies needs further study.
These results suggested that compared with other
TRDV and TRGV repertoire, some donors’ TRDV1
repertoire might be more sensitive to GVHD-associated
antigens after G-CSF mobilization, causing the occur-
rence of GVHD; whereas TRDV1 repertoire of most
donors maintained stability after G-CSF mobilization,
resulting in low incidence of GVHD. Therefore, TRDV1
repertoire might be used as an observation index for
GVHD in the future. In short, our studies observed that
some repertoire of gδ
+ T cells changed after G-CSF
mobilization. Accordingly, the antigens recognized by
them might change, thereby altering the immune
responses of gδ
+ T cells and mediating the occurrence
of GVHD. However, the mechanisms are still not well
understood and need further study.
Conclusions
We characterized the distribution and clonality of TRGV
and TRDV subfamilies of donor T cells before and after
G-CSF mobilization. The results show that G-CSF
mobilization not only influences the distribution and
expression levels of TRGV and TRDV repertoire, but
also changes the clonality of gδ
+ T cells. This alteration
of TRGV and TRDV repertoire might play a role in
mediating GVHD in G-CSF mobilized allo-PBSCT.
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